

## **Zeren Wang, Ph. D.**



Dr. Zeren Wang is the Chairman of the Board and Chief Scientific Officer at Shenzhen Pharmacin Co., Ltd. in China, overseeing the company's overall scientific and technical development. Before joining Shenzhen Pharmacin, Dr. Wang served as the Director of Formulation Development at Boehringer Ingelheim Pharmaceuticals in the U.S., where he led a team responsible for the formulation and process development of New Chemical Entities (NCEs). His role encompassed strategic leadership, organizational excellence, and alignment with international counterparts, and he briefly served as the interim head of Pharmaceuticals from 2009 to 2010. During his time at Boehringer Ingelheim, he managed various aspects of drug development, including process technology, material characterization, scale-up, technology transfer, regulatory submissions, and product launches. He was also responsible for introducing several new formulation technologies, including SEDDS (self-emulsifying drug delivery systems), solid dispersion techniques (spray drying and melt extrusion), and nano-milling. Dr. Wang is an expert in developing formulations for poorly water-soluble compounds for oral delivery and has experience with oral solid dosage forms (such as tablets and capsules), oral liquids (solutions and suspensions), controlled release technology, and parenterals (lyophilization). Prior to his role at Boehringer Ingelheim, he worked at Novartis Pharmaceuticals and Eisai Inc. Dr. Wang holds a PhD in Physical Pharmacy from the University of Utah and has published 30 peer-reviewed articles and patents, along with numerous poster presentations.

## **Timothy S. Tracy, Ph.D.**

Dr. Timothy S. Tracy is an expert in clinical pharmacology and a Fellow with the American Association of Pharmaceutical Scientists, Dr. Tracy holds three patents related to drug delivery systems and has published over 100 scientific manuscripts, fifteen book chapters and edited two books. Dr. Tracy's expertise is in the areas of drug metabolism, pharmacokinetics and pharmacogenetics, as well as the larger field of clinical pharmacology and he has conducted numerous clinical trials. Most recently, he served as CEO of Aprelia Pharmaceuticals, a 3D printing pharmaceutical company.

He has served as a consultant to the pharmaceutical industry since 2003. He has served as a subject matter expert with respect to drug metabolism and clinical pharmacology, designing

experiments, negotiating with CROs for completion of work, analyzing the generated data, generating reports and then designing additional in vitro and in vivo studies. With respect to regulatory contributions, he has assisted with pre-IND and IND submissions and has served as a representative at FDA meetings.

Dr. Tracy received his bachelor's degree in pharmacy from Ohio Northern University, his PhD in clinical pharmacy from Purdue University, and completed a postdoctoral fellowship in clinical pharmacology at Indiana University.

### **Usha Pillai, Ph.D., PMP**

Dr. Usha Pillai brings over three decades of experience in the pharmaceutical industry, academia, and consulting. Her extensive industry knowledge has been instrumental in her decade-long consultancy work with biotech companies.

Usha serves on the Connecticut Bioscience Growth Council, the Advisory Board of the Biotechnology Academic and Career Pathway (BioPath), the Interfaith Volunteer Care Givers of New Haven, and the Garde Arts Center in New London, CT.

Prior to founding Aria Management Consulting, which specializes in strategic planning, business operations, and program management, Usha held progressively responsible positions at Pfizer, Inc. She is a certified Project Management Professional (PMP) and holds a Bachelor's degree in Pharmacy; an Executive Masters in Technology Management; and a Ph. D. in Pharmaceutical Sciences. Additionally, she was a post-doctoral fellow at the University of Arizona in Tucson, AZ.